v3.26.3
Share based compensation reserve - Director and Senior Management Share Awards (Details)
€ in Millions
9 Months Ended
Jun. 22, 2026
shares
Jun. 22, 2026
Jul. 10, 2025
shares
Jul. 10, 2024
Sep. 30, 2026
EUR (€)
shares
Sep. 30, 2025
EUR (€)
shares
Key Management Personnel Of Entity Or Parent, Non-Executive Director [Member]            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
New awards granted in the period (in shares)   94,110 49,092 36,738    
Awards vested and issued in period (in shares) (49,092) (29,707)       (24,135)
Liabilities from share-based payment transactions (in shares) 19,385   12,603      
New awards granted in the period (in shares)   94,110 49,092 36,738    
Share based compensation reserve | Key Management Personnel Of Entity Or Parent, Non-Executive Director [Member]            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Share based payment credit | €         € 0.6 € 0.5
Share based compensation reserve | Key management personnel of entity or parent            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Share based payment credit | €         (6.9) 6.2
Share based compensation reserve | Key Management Personnel Of Entity Or Parent, Reclassification to tax liability            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Issue of ordinary shares | €         (1.6) (12.6)
Reclassification of awards for settlement of tax liabilities | €         € (0.5) € (5.0)
Restricted shares            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         3,285,141 3,128,416
New awards granted in the period (in shares)         1,336,055 1,262,731
Forfeitures in the period (in shares)         (1,263,159) (343,439)
Awards vested and issued in period (in shares)         (49,000) (631,994)
Number of other equity instruments outstanding (in shares) at end of period         3,309,037 3,415,714
New awards granted in the period (in shares)         1,336,055 1,262,731
Restricted shares | January 1, 2022            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Awards vested and issued in period (in shares)           (349,823)
Liabilities from share-based payment transactions (in shares)           282,171
Restricted shares | Other Awards            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Awards vested and issued in period (in shares)         (62,000)
Restricted shares | January 1, 2022            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period           704,983
New awards granted in the period (in shares)           0
Forfeitures in the period (in shares)           (148,989)
Awards vested and issued in period (in shares)           (555,994)
Number of other equity instruments outstanding (in shares) at end of period           0
New awards granted in the period (in shares)           0
Restricted shares | Other Awards            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         589,991 441,991
New awards granted in the period (in shares)         179,027 62,000
Forfeitures in the period (in shares)         (24,167) (20,000)
Awards vested and issued in period (in shares)         (49,000) (76,000)
Number of other equity instruments outstanding (in shares) at end of period         695,851 407,991
New awards granted in the period (in shares)         179,027 62,000
Restricted shares | January 1, 2023            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         777,155 922,250
New awards granted in the period (in shares)         0 0
Forfeitures in the period (in shares)         (777,155) (70,695)
Awards vested and issued in period (in shares)         0  
Number of other equity instruments outstanding (in shares) at end of period         0 851,555
New awards granted in the period (in shares)         0 0
Restricted shares | January 1, 2024            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         873,507 1,059,192
New awards granted in the period (in shares)         0 0
Forfeitures in the period (in shares)         (94,246) (77,871)
Awards vested and issued in period (in shares)         0  
Number of other equity instruments outstanding (in shares) at end of period         779,261 981,321
New awards granted in the period (in shares)         0 0
Performance and Restricted Stock | January 1, 2025            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         1,044,488 0
New awards granted in the period (in shares)         0 1,200,731
Forfeitures in the period (in shares)         (248,192) (25,884)
Awards vested and issued in period (in shares)         0  
Number of other equity instruments outstanding (in shares) at end of period         796,296 1,174,847
New awards granted in the period (in shares)         0 1,200,731
Performance and Restricted Stock | January 1, 2026            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         0  
New awards granted in the period (in shares)         1,157,028  
Forfeitures in the period (in shares)         (119,399)  
Awards vested and issued in period (in shares)         0  
Number of other equity instruments outstanding (in shares) at end of period         1,037,629  
New awards granted in the period (in shares)         1,157,028